ACCESSIBILITY

24/7

Headlines

18:20

The World Cup warning: Riots don’t start in the streets. They start online

18:07

“There’s a price where you have to say yes”: CyberArk founder on the $25 billion Palo Alto deal

14:18

"If there is no significant change, we will see a 25%-30% reduction in high-tech's workforce"

13:32

“There is no better solution for Zim than the one we created”

Buzz

Most popular

Daily

Weekly

"If an engineer in Ireland costs 20% less, it is clearly part of the consideration when deciding where to expand"

Iron Dome and Iron Beam maker Rafael unveils new weapon against the drone threat

Echo: “Employees have become very good at identifying performative culture”

"If there is no significant change, we will see a 25%-30% reduction in high-tech's workforce"

More than 50 years after its debut, Israel's Kfir fighter jet gets a new lease on life

More news

Pharma

15 stories about Pharma

Employees Protest Outside Teva’s Israeli Facilities

14.12.17|Omer Kabir, Yoav Stoler and Keren-Or Grinberg

The demonstrations outside the company's facilities held Thursday foreshadow a full-out strike planned by the company’s employees for Sunday

Teva to Let Go 14,000 Employees Over the Next Two Years

14.12.17|Lilach Baumer

The company released a statement detailing its reconstruction plan Thursday. CEO Kåre Schultz elaborated on the plan during a call with investors

Israeli Pharma Company Wavelength Appoints New CEO

30.11.17|CTech

Pharma veteran Iftach Seri was named as Wavelength’s CEO. Formerly a Perrigo subsidiary, the company was recently sold to New York-based investment firm SK Capital for $110 million

Teva Announces Restructuring, Ousts Second in Command

27.11.17|Golan Hazani

The troubled Israeli drugmaker has combined its generic and specialty drug divisions, effective immediately

Generic Focus made Kite Pharma Founder Leave Teva

13.11.17|Dror Reich

Founder of cancer treatment company sold to Gilead Sciences for $12 billion, says Gilead wants “to crack the cancer market"

With New CEO in Seat, Teva Lowers Outlook

02.11.17|Lilach Baumer and Dror Reich

Outlook reflects an earlier than expected launch of a generic competitor to Teva’s multiple sclerosis drug Copaxone

Former Teva Executive One Step Closer to Bringing Copaxone Rival to Market

31.10.17|Lilach Baumer

Mapi Pharma announced a successful phase II clinical trial for its Copaxone equivalent GA Depot

Teva Loses Copaxone Market Exclusivity

04.10.17|Lilach Baumer

Rival Mylan received FDA approval for its generic versions of Copaxone, Teva’s flagship drug

New CEO to Break Teva’s Copaxone Habit

11.09.17|Sophie Shulman, Dror Reich

Troubled drugmaker says new CEO must work to quickly regain its financial credibility

Teva Appoints Lundbeck's Schultz as CEO

11.09.17|Dror Reich and Micky Grunfeld

The company’s announcement brings an end to a seven month search for a CEO to lead the troubled generic drugmaker. Updated

Acne Cream Developer Sol-Gel files for $86 Million Nasdaq IPO

31.08.17|Dror Reich

The clinical-stage drug developer will remain a "controlled company" under current shareholder Arkin Dermatology

Anti-Acne Drug Developer Plans Nasdaq IPO

15.08.17|Golan Hazani

Sol-Gel approached potential underwriters. It aims to go public before the end of the year

Allergan Sketches Road Show to Sell Teva Stake

14.08.17|Golan Hazani

The company is in discussions with investment bankers and brokers to sell its Teva shares, said one person familiar with the matter

With Bloated Debt, Teva Looks to Sell Assets

10.08.17|Eli Shimony and Gil Kalian

The generic drugmaker said it is looking to sell Medis, an Iceland-based company it bought in 2016

Teva’s Perfect Storm Sends Tel-Aviv Stock Exchange Down

06.08.17|Calcalist

Teva’s stock price dropped sharply on Thursday and Friday after the company released quarterly revenue and profits that fell short of analysts’ forecasts